Table 1 Participant clinical features of the follow-up cohort
Follow-up (n = 26) | ||
|---|---|---|
Age (years) | Median (min, max) | 9.4 (4.1, 17.8) |
Sex (%) | Males | 18 (69) |
Parental smokers (%) | Total | 3 (12) |
Previous adrenaline required (%) | Total | 6 (23) |
Other food allergy (%) | Total | 11 (42) |
Allergic rhinitis (%) | Total | 17 (65) |
AR severity for those with AR—max = 4a | Median (min, max) | 4 (1, 4) |
Eczema ever (%) | Total | 22 (85) |
Eczema active treatment (%) | Total | 12 (46) |
SCORAD for those with visible eczema | Median (min, max) | 10.9 (3.0, 28.9) |
Asthma ever (%) | Total | 17 (65) |
Current preventer (%) | Total | 12 (46) |
Current reliever (%) | Total | 15 (58) |
Anaphylaxis in challenge (%) | Total | 5 (19) |
CANA in challenge (%) | Total | 9 (35) |
No allergy in challenge (%) | Total | 12 (46) |
Ara h2 SPT (mm) | Median (min, max) | 3.8 (0.0, 9.0) |
Peanut SPT (mm) | Median (min, max) | 6.3 (0.0, 13.0) |
Ara h2 sIgE (kU/L) | Median (min, max) | 0.66 (0.00, 22.10) |
Peanut sIgE (kU/L) | Median (min, max) | 0.99 (0.01, 35.60) |
FeNO (p.p.b)b | Median (min, max) | 24.3 (2.7, 119.2) |